MORF-057

Phase 2Small molecule

Eli Lilly

MORF-057 is one of 37 small molecule programs targeting Inflammatory Bowel Diseases. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Inflammatory Bowel DiseasesRecruiting

AdultActive, not recruiting

Inflammatory Bowel DiseasesPhase 2

Recruiting

AdultPhase 2

Active, not recruiting

Competition

Competitive Landscape

127 competitors in Adult

#DrugCompanyPhaseTrials

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 2

Tebrazid

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 3

1 3

Mounjaro

Eli Lilly

Phase 2

1 4

Rifampicin

Boehringer Ingelheim

Phase 3

3 5

Myqorzo

CCytokinetics

Phase 3

1 6

Opzelura

DDizal Pharmaceuticals

Phase 2

1 7

Cabenuva

GSK

Phase 1

6 8

NM8074

NNovelMed Therapeutics

Phase 2

2 9

EB-1020

Otsuka

Phase 3

1 10

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2Recruiting

Inflammatory Bowel Diseases

NCT06226883

Clinical

Trials by Indication[1]

Adult1 trial

A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT05611671·280 enrolled

Efficacy and Safety1 trial

A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT05291689·39 enrolled

Inflammatory Bowel Diseases1 trial

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (GARNET)

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT06226883·385 enrolled

Unspecified1 trial

Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT04580745·67 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for MORF-057. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MORF-057 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MORF-057. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Eli Lilly

MORF-057

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Adult1 trial

Efficacy and Safety1 trial

Inflammatory Bowel Diseases1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News